Ex vivo drug sensitivity assay correlates with clinical response in pediatric AML

Listen to the exciting results from Notable’s collaboration with Texas Children’s Cancer Center highlighting response prediction in a pediatric acute myeloid leukemia (AML) study that was presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. The data was presented by Dr. Alexandra Stevens from Texas Children’s and demonstrates the correlation of functional drug sensitivity screening using Notable’s predictive technology platform with the clinical outcomes of pediatric patients.